The opioid-induced constipation treatment global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Opioid-Induced Constipation Treatment Market, 2024report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size – The opioid-induced constipation treatment market size has grown strongly in recent years. It will grow from $1.66 billion in 2023 to $1.78 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to expanding geriatric population, personalized OIC treatments, availability of effective OIC drugs, increasing prevalence of opioid use, and rising prevalence of gastrointestinal disorders.
The opioid-induced constipation treatment market size is expected to see strong growth in the next few years. It will grow to $2.31 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to accelerated drug approval initiatives, increasing use of opioid analgesic prescriptions, surging expenditure on the R And D of novel treatments, and an increase in development of biologics. Major trends in the forecast period include patient education and awareness, the emergence of targeted therapies, non-pharmacological interventions, biotechnology innovations, and increased investment.
Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report
Scope Of Opioid-Induced Constipation Treatment Market
The Business Research Company’s reports encompass a wide range of information, including:
- Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
- Drivers: Examination of the key factors propelling market growth.
- Trends: Identification of emerging trends and patterns shaping the market landscape.
- Key Segments: Breakdown of the market into its primary segments and their respective performance.
- Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
- Macro Economic Factors: Assessment of broader economic elements impacting the market.
Opioid-Induced Constipation Treatment Market Overview
Market Drivers -The rise in the administration of opioids for cancer and non-cancer pain is expected to propel the growth of the opioid-induced constipation treatment market going forward. Cancer pain refers to pain associated with cancer and its treatment, while non-cancer pain refers to pain from conditions unrelated to cancer. Administration of opioids for cancer and non-cancer pain is driven by the need to effectively manage moderate to severe pain, considering factors such as the intensity and duration of pain, patient response to other treatments, and the overall goal of improving quality of life while minimizing potential risks of addiction and side effects. Opioid-induced constipation (OIC) treatment helps patients with cancer and non-cancer pain by relieving constipation caused by opioid use, thereby improving overall comfort, adherence to pain management regimens, and quality of life without compromising pain relief. For instance, in April 2023, according to the Center for Disease Control and Prevention (CDC), a US-based national public health agency, during 2021, approximately 20.9% of U.S. adults (51.6 million people) reported experiencing chronic pain, and 6.9% (17.1 million people) experienced high-impact chronic pain, which significantly limits daily activities. Therefore, the rise in the administration of opioids for cancer and non-cancer pain is driving the growth of the opioid-induced constipation treatment market.
Market Trends – Major companies operating in the opioid-induced constipation treatment market are developing mu-opioid receptor antagonists to address the specific needs of patients suffering from opioid-induced constipation (OIC). Mu-opioid receptor antagonists offer a targeted approach to managing opioid-induced constipation, helping patients maintain bowel regularity while undergoing opioid therapy for pain management. For instance, in December 2021, Shionogi & Co. Ltd. a Japan-based pharmaceutical company received approval for Symproic (naldemedine) tablets for the treatment of opioid-induced constipation in adult patients in Taiwan. Symproic is a peripherally acting mu-opioid receptor antagonist that helps relieve constipation caused by opioid use. The approval in Taiwan expands the availability of Symproic as a treatment option for OIC, offering relief to patients suffering from this condition.
The opioid-induced constipation treatment market covered in this report is segmented –
1) By Drug Class: Laxatives, Peripherally Acting µ-opioid Receptor Antagonists, Serotonin Receptor Agonists, Prostaglandin
2) By Type: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Get an inside scoop of the opioid-induced constipation treatment market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp
Regional Insights – North America was the largest region in the opioid-induced constipation treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies – Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Chemical Pharma Co. Ltd., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH., Shionogi & Co. Ltd., Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Mundipharma International Limited, Lantheus Holdings Inc., Indivior plc, Mallinckrodt Pharmaceuticals, Collegium Pharmaceutical Inc., Ironwood Pharmaceuticals Inc., Cosmo Pharmaceuticals SA, Nektar Therapeutics, RedHill Biopharma Ltd., Theravance Biopharma Inc., Cumberland Pharmaceuticals Inc., Valinor Pharma LLC
Table of Contents
1. Executive Summary
2. Opioid-Induced Constipation Treatment Market Characteristics
3. Opioid-Induced Constipation Treatment Market Trends And Strategies
4. Opioid-Induced Constipation Treatment Market – Macro Economic Scenario
5. Global Opioid-Induced Constipation Treatment Market Size and Growth
……………………………….
32. Global Opioid-Induced Constipation Treatment Market Competitive Benchmarking
33. Global Opioid-Induced Constipation Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Opioid-Induced Constipation Treatment Market
35. Opioid-Induced Constipation Treatment Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
